Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsSolid TumorsProtocol groupDermatologic OncologyT-Cell and NK-Cell NeoplasmsDiseaseNHL, T-Cell Type, Cutaneous, UnspecifiedNHL, T-Cell Type, Cutaneous Primary, CD30-PositiveNHL, T-Cell Type, Mycosis FungoidesNHL, T-Cell Type, Sézary SyndromeSubgroupCD30+ICD10C84.0C84.1C84.8C86.6MeSHLymphoma, T-Cell, CutaneousMycosis FungoidesSezary SyndromeSequenceChemotherapyChemo-substanceBrentuximab vedotinDoxorubicin pegylated liposomalGemcitabineChemo-substanceBrentuximab vedotinDoxorubicin pegylated liposomalGemcitabineChemo-substanceBrentuximab vedotinDoxorubicin pegylated liposomalGemcitabineChemo-substanceBrentuximab vedotinDoxorubicin pegylated liposomalGemcitabineNo. Substances1 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronPyridoxineSupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronPyridoxineSupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronPyridoxineSupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronPyridoxineNo. Substances24Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationSecond lineseveral possibleThird line Therapy phaseTherapy intentionpalliativeRisksAnemia Hb below 8g/dlAstheniaDiarrheaEmetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaHand-Foot SyndromeLeukopeniaMucositisNauseaNeuropathyNeutropeniaPruritusSepsisThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorDuvic MPrince HMQuereux GDiseasefortgeschrittenes, kutanes T-Zell-Lymphomkutanes T-Zell-Lymphom, CD30+, mindestens eine Vortherapie, ECOG 0-2refraktäres oder rezidivierendes kutanes T-Zell-Lymphom, 2 oder mehr Vorbehandlungen, ECOG 0-2OriginDepartment of Dermatology, The University of Texas M. D. Anderson Cancer Center, HoustonDepartments of Dermatology, Centre Hospitalier Universitaire, Nantes, FranceDivision of Cancer Medicine, Peter MacCallum Cancer Centre, The University of Melbourne, ALCANZAProtocols in Revision 3 protocols foundProtocols under revision.Brentuximab Vedotin 1.8, cutaneous T-cell lymphoma (PID1389 V1.0)Gemcitabine 1000, cutaneous T-cell lymphoma (PID1388 V1.0)Pegylated Doxorubicin Liposomal 40, cutaneous T-cell lymphoma (PID1387 V1.0)
